Actively Recruiting
Phase 12 Open-label Study of ETX-929, a Pan-KRAS Inhibitor, Alone and With Cetuximab in People With Advanced Solid Tumors Having KRAS Mutations
Led by Ensem Therapeutics · Updated on 2026-11-03
320
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 12, open-label, multi-center study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary effectiveness of ETX-929 in people with advanced solid tumors that have a KRAS mutation. The study aims to evaluate ETX-929 both as a single treatment and in combination with cetuximab to better understand its potential use in treating these cancers. The study consists of four parts Part A tests increasing doses of ETX-929 alone Part B tests increasing doses of ETX-929 combined with a fixed dose of cetuximab Parts C and D expand enrollment to further evaluate ETX-929 alone and in combination at doses recommended from earlier phases. Each part includes a 28-day screening period followed by treatment cycles. ETX-929 is given orally once daily in 21- or 28-day cycles, while cetuximab is administered intravenously every two weeks during combination therapy. Participants will undergo screening to confirm eligibility, then receive study treatments with regular monitoring. Researchers will assess safety and tolerability throughout treatment and select recommended doses for further study. They will also evaluate measures of treatment efficacy, pharmacokinetics, and pharmacodynamics over about six months. This study lasts until April 2029, with ongoing safety and effectiveness evaluations during and after treatment periods.
CONDITIONS
Brief Title
Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors
Research Team
L
Lori Cykowski
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here